CFTR and cystic fibrosis: A Phase 2B trial in CF patients of various genotypes evaluating pGM169/GL67A, a nebulized liposomal vector carrying the CFTR gene, demonstrated an improvement in FEV1 compared to placebo by 3.7% predicted at 12-months follow-up [32].